Analysis of literature-derived duplicate records in the FDA Adverse Event Reporting System (FAERS) database

被引:1
|
作者
Han, Weiru [1 ]
Morris, Robert [2 ,3 ]
Bu, Kun [1 ]
Zhu, Tianrui [2 ]
Huang, Hong [4 ]
Cheng, Feng [2 ,3 ]
机构
[1] Univ S Florida, Coll Art & Sci, Dept Math & Stat, Tampa, FL 33620 USA
[2] Univ S Florida, Taneja Coll Pharm, Dept Pharmaceut Sci, Tampa, FL 33613 USA
[3] Univ S Florida, Coll Publ Hlth, Dept Biostat & Epidemiol, Tampa, FL 33613 USA
[4] Univ S Florida, Sch Informat, Tampa, FL 33620 USA
基金
美国国家卫生研究院;
关键词
pharmacovigilance; PubMed; adverse drug events; text comparison; FAERS Dashboard; DEMENTIA; MEDWATCH; PATIENT;
D O I
10.1139/cjpp-2024-0078
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The FDA Adverse Event Reporting System (FAERS) is a large-scale repository of reports concerning adverse drug events (ADEs). The same published clinical study or report may be reviewed by multiple companies or healthcare professionals and reported separately to the FDA, leading to a significant presence of duplicate reports in FAERS. These duplicate records can result in the identification of false associations between a given drug and an ADE. In this study, we first assessed the consistency of drug and ADE information in FAERS reports from Alzheimer's disease patients. Our findings showed greater congruence in drug-related information compared to ADE-related information, likely due to the greater heterogeneity and variety of terms or phrases used to describe ADEs. We then demonstrated that text comparison methods are effective in identifying duplicate records based on literature citations, testing 10 different comparison functions for their overall efficacy. Token-based methods (such as COSINE, QGRAM, and JACCARD), edit-based approaches (including OSA, LV, and DL), and sequence-based techniques like LCS have proven highly effective in accurately detecting identical publications within free text, demonstrating both high sensitivity and specificity. These results offer valuable insights for identifying duplicate FAERS reports and improving the reliability of detected associations between drugs and ADEs.
引用
收藏
页码:56 / 69
页数:14
相关论文
共 50 条
  • [21] A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
    Shu-peng Zou
    Hai-yun Yang
    Meng-ling Ouyang
    Qian Cheng
    Xuan Shi
    Ming-hui Sun
    BMC Pharmacology and Toxicology, 24
  • [22] Adverse events associated with brolucizumab: a disproportionality analysis of the FDA adverse event reporting system (FAERS)
    Xiong, Xiaomei
    Zhang, Xiuwen
    Li, Xiaoxia
    Huang, Taomin
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (11) : 1447 - 1452
  • [23] A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
    Zou, Shu-peng
    Yang, Hai-yun
    Ouyang, Meng-ling
    Cheng, Qian
    Shi, Xuan
    Sun, Ming-hui
    BMC PHARMACOLOGY & TOXICOLOGY, 2023, 24 (01):
  • [24] Atezolizumab and severe cutaneous adverse reactions: Data mining of the FDA Adverse Event Reporting System (FAERS) database
    Pecere, A.
    Bisinella, G. C.
    ANNALS OF ONCOLOGY, 2021, 32 : S1251 - S1251
  • [25] Alpelisib-related adverse events: The FDA Adverse Event Reporting System Database (FAERS) pharmacovigilance study
    Li, Yun
    Li, Hang
    Xiang, Zhongyuan
    HELIYON, 2024, 10 (06)
  • [26] Carfiilzomib-induced cardiotoxicity: An analysis of the FDA Adverse Event Reporting System (FAERS)
    Buck, Benjamin
    Kellett, Eric
    Addison, Daniel
    Vallakati, Ajay
    JOURNAL OF THE SAUDI HEART ASSOCIATION, 2022, 34 (03) : 134 - 141
  • [27] Disproportionality Analysis of Safety with Nafcillin and Oxacillin with the FDA Adverse Event Reporting System (FAERS)
    Timbrook, Tristan T.
    McKay, Lydia
    Sutton, Jesse D.
    Spivak, Emily S.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (03)
  • [28] The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
    Caruso, I.
    Di Gioia, L.
    Di Molfetta, S.
    Caporusso, M.
    Cignarelli, A.
    Sorice, G. P.
    Laviola, L.
    Giorgino, F.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2024, 47 (11) : 2671 - 2678
  • [29] Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
    Zhou, Chaozheng
    Peng, Shengkun
    Lin, Anqi
    Jiang, Aimin
    Peng, Yuanxi
    Gu, Tianqi
    Liu, Zaoqu
    Cheng, Quan
    Zhang, Jian
    Luo, Peng
    ECLINICALMEDICINE, 2023, 59
  • [30] Real-world pharmacovigilance analysis of galsulfase: a study based on the FDA adverse event reporting system (FAERS) database
    Li, Shangze
    Huang, Runcheng
    Meng, Yuanyuan
    Liu, Yijia
    Qian, Jiao
    Zou, Junjie
    Yang, Jun
    FRONTIERS IN PHARMACOLOGY, 2024, 15